Published in J Lipid Res on February 01, 2004
Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biol (2009) 2.24
Mycobacterium tuberculosis induces an atypical cell death mode to escape from infected macrophages. PLoS One (2011) 1.31
Group XV phospholipase A₂, a lysosomal phospholipase A₂. Prog Lipid Res (2010) 0.90
Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis. Respir Res (2012) 0.83
Enhancing enhancers: new complexities in the retinoid regulation of gene expression. Biochem J (2004) 0.75
Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med (2010) 1.62
Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses. J Virol (2009) 1.61
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab (2007) 1.61
Loss of Chd7 function in gene-trapped reporter mice is embryonic lethal and associated with severe defects in multiple developing tissues. Mamm Genome (2007) 1.58
Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation (2005) 1.28
The ATP-dependent chromatin remodeling enzyme CHD7 regulates pro-neural gene expression and neurogenesis in the inner ear. Development (2010) 1.24
Lysosomal phospholipase A2 and phospholipidosis. Mol Cell Biol (2006) 1.23
Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab (2008) 1.21
Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology (2009) 1.16
Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol (2003) 1.15
Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages. J Biol Chem (2004) 1.11
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis (2010) 1.10
Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J Am Soc Nephrol (2009) 1.09
Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. J Biol Chem (2002) 1.07
Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One (2010) 1.04
Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice. J Biol Chem (2007) 1.02
The secretion and uptake of lysosomal phospholipase A2 by alveolar macrophages. J Immunol (2008) 1.00
A role for lysosomal phospholipase A2 in drug induced phospholipidosis. Drug Metab Lett (2007) 1.00
An in vitro model of Fabry disease. J Am Soc Nephrol (2005) 1.00
Ceramide 1-phosphate, a mediator of phagocytosis. J Biol Chem (2005) 0.99
Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol (2008) 0.99
Phacoemulsification associated corneal damage evaluated by corneal volume. Am J Ophthalmol (2006) 0.98
Calcium-independent phospholipase A2 beta is dispensable in inflammasome activation and its inhibition by bromoenol lactone. J Innate Immun (2009) 0.97
Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One (2010) 0.95
Structure and function of lysosomal phospholipase A2: identification of the catalytic triad and the role of cysteine residues. J Lipid Res (2005) 0.94
The role of negatively charged lipids in lysosomal phospholipase A2 function. J Lipid Res (2009) 0.93
Ceramides and glucosylceramides are independent antagonists of insulin signaling. J Biol Chem (2013) 0.92
Mapping mechanisms and charting the time course of premature cell senescence and apoptosis: lysosomal dysfunction and ganglioside accumulation in endothelial cells. Am J Physiol Renal Physiol (2007) 0.92
The acylation of lipophilic alcohols by lysosomal phospholipase A2. J Lipid Res (2007) 0.92
Lowering glycosphingolipid levels in CD4+ T cells attenuates T cell receptor signaling, cytokine production, and differentiation to the Th17 lineage. J Biol Chem (2011) 0.90
Src kinase mediates the regulation of phospholipase C-gamma activity by glycosphingolipids. J Biol Chem (2003) 0.90
Sphingosine kinase 1-mediated inhibition of Fas death signaling in rheumatoid arthritis B lymphoblastoid cells. Arthritis Rheum (2006) 0.90
Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. J Lipid Res (2008) 0.88
Regulation of phospholipase C-gamma activity by glycosphingolipids. J Biol Chem (2002) 0.88
Positional specificity of lysosomal phospholipase A2. J Lipid Res (2006) 0.88
A turn in the road: How studies on the pharmacology of glucosylceramide synthase inhibitors led to the identification of a lysosomal phospholipase A2 with ceramide transacylase activity. Glycoconj J (2004) 0.87
Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res (2011) 0.87
Granulocyte colony-stimulating factor primes NADPH oxidase in neutrophils through translocation of cytochrome b(558) by gelatinase-granule release. J Lab Clin Med (2002) 0.86
The measurement of lysosomal phospholipase A2 activity in plasma. J Lipid Res (2010) 0.86
Lysosomal phospholipase A2 activity in pig aqueous humor. Invest Ophthalmol Vis Sci (2012) 0.85
Role for lysosomal phospholipase A2 in iNKT cell-mediated CD1d recognition. Proc Natl Acad Sci U S A (2013) 0.85
Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse. Am J Physiol Heart Circ Physiol (2009) 0.84
Regulation of polymorphonuclear leukocyte degranulation and oxidant production by ceramide through inhibition of phospholipase D. Blood (2002) 0.84
Globoside promotes activation of ERK by interaction with the epidermal growth factor receptor. Biochim Biophys Acta (2012) 0.82
Permanent bilateral cortical blindness due to reversible posterior leukoencephalopathy syndrome. J Nippon Med Sch (2011) 0.82
Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke (2006) 0.81
Ceramide-1-phosphate in phagocytosis and calcium homeostasis. Adv Exp Med Biol (2010) 0.81
Ceramide inhibition of phospholipase D and its relationship to RhoA and ARF1 translocation in GTP gamma S-stimulated polymorphonuclear leukocytes. Blood (2003) 0.81
1-O-acylceramides are natural components of human and mouse epidermis. J Lipid Res (2013) 0.80
Ceramide kinase promotes Ca2+ signaling near IgG-opsonized targets and enhances phagolysosomal fusion in COS-1 cells. J Lipid Res (2007) 0.80
Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice. Neurochem Res (2013) 0.80
Glycosphingolipid Mediated Caveolin-1 Oligomerization. J Glycomics Lipidomics (2012) 0.79
Phagocytic signaling molecules in lipid rafts of COS-1 cells transfected with FcgammaRIIA. Biochem Biophys Res Commun (2005) 0.78
A fluorogenic phospholipid for the detection of lysosomal phospholipase A2 activity. Anal Biochem (2012) 0.77
Lysosomal phospholipase A2: a novel player in host immunity to Mycobacterium tuberculosis. Eur J Immunol (2014) 0.77
Alpha-galactosidase A in vascular disease. Trends Cardiovasc Med (2007) 0.77
Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A. Am J Physiol Gastrointest Liver Physiol (2013) 0.77
Thinking about rare kidney diseases. J Am Soc Nephrol (2005) 0.76
Enhanced phagocytosis through inhibition of de novo ceramide synthesis. J Biol Chem (2002) 0.76
Effect of Antiglaucoma Medicine on Intraocular Pressure in DBA/2J Mice. Ophthalmic Res (2016) 0.75